Gossamer Bio, Inc. (GOSS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 7.56 |
| Open | 7.58 |
| Bid | 7.37 x 2900 |
| Ask | 7.64 x 800 |
| Day's Range | 7.23 - 7.71 |
| 52 Week Range | 5.64 - 14.30 |
| Volume | |
| Avg. Volume | 866,177 |
| Market Cap | 589.172M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.11 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.70 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GOSS
Related Research
- Gossamer Bio, Inc.Technical Assessment: Bearish in the Intermediate-TermThe stock market soared on Tuesday, so it's not surprising that Wednesday was flat -- but we certainly had a lot of good intermarket news. Yields fell across the curve, crude oil and some grain and soft commodity prices got hammered, and the U.S. Dollar Index fell slightly. If you are bullish on stocks, you can't ask for much more than that.RatingFair ValueEconomic Moat2 days agoArgus Research
- Business Wire
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
SAN DIEGO, June 09, 2022--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH). The article, entitled "Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arteria
- Zacks
Wall Street Analysts Believe Gossamer Bio (GOSS) Could Rally 113%: Here's is How to Trade
The mean of analysts' price targets for Gossamer Bio (GOSS) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks
Gossamer Bio (GOSS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Gossamer Bio (GOSS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
